|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 60.74 USD | +1.47% |
|
-2.02% | +12.61% |
| Feb. 11 | Tranche Update on Bristol-Myers Squibb Company's Equity Buyback Plan announced on October 27, 2016. | CI |
| Feb. 09 | AstraZeneca's Evinova Enters Clinical Development AI Partnership Deal | MT |
Business description: Bristol-Myers Squibb Company
The United States account for 69.1% of net sales.
Number of employees: 32,500
Sales by Activity: Bristol-Myers Squibb Company
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Pharmaceuticals | 46.38B | 46.16B | 45.01B | 48.3B | 48.19B |
Geographical breakdown of sales: Bristol-Myers Squibb Company
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 29.21B | 31.83B | 31.56B | 34.1B | 33.28B |
International | - | 13.5B | 12.75B | 13.2B | 13.83B |
Unallocated | 852M | 834M | 699M | 996M | 1.09B |
Europe | 10.69B | - | - | - | - |
Rest of The World | 5.63B | - | - | - | - |
Executive Committee: Bristol-Myers Squibb Company
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 2023-10-31 | |
David Elkins
DFI | Director of Finance/CFO | 58 | 2019-11-19 |
| Compliance Officer | - | 2023-09-30 | |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | 53 | - |
| Chief Tech/Sci/R&D Officer | - | - |
Composition of the Board of Directors: Bristol-Myers Squibb Company
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 55 | 2024-03-31 | |
Peter Arduini
BRD | Director/Board Member | 61 | 2016-03-31 |
Theodore Samuels
BRD | Director/Board Member | 71 | 2017-02-20 |
Karen Vousden
BRD | Director/Board Member | 68 | 2017-12-31 |
Julia Haller
BRD | Director/Board Member | 71 | 2019-11-19 |
Phyllis Yale
BRD | Director/Board Member | 68 | 2019-11-19 |
Paula Price
BRD | Director/Board Member | 64 | 2020-08-31 |
Derica Rice
BRD | Director/Board Member | 61 | 2020-08-31 |
Manuel Medina
BRD | Director/Board Member | 58 | 2021-05-31 |
Deepak Bhatt
BRD | Director/Board Member | 58 | 2022-06-13 |
Holdings: Bristol-Myers Squibb Company
| Name | Equities | % | Valuation |
|---|---|---|---|
| 5,075,304 | 3.53% | 368 M $ | |
UNIQURE N.V. 3.83% | 2,388,108 | 3.83% | 54 M $ |
PRIME MEDICINE, INC. 6.38% | 11,006,163 | 6.38% | 42 M $ |
| 70,231,140 | 16.86% | 22 M $ | |
COMPUGEN LTD. 1.97% | 1,840,136 | 1.97% | 3 M $ |
COMPUGEN LTD. 1.59% | 177,761 | 1.59% | 1 M $ |
COMPUGEN LTD. 1.63% | 200,244 | 1.63% | 776 947 $ |
CELULARITY INC. 1.78% | 426,372 | 1.78% | 520 174 $ |
Company details: Bristol-Myers Squibb Company
Bristol Myers Squibb Co.
Route 206 & Province Line Road
08543, Princeton
+609 252 4621
http://www.bms.com
Group companies: Bristol-Myers Squibb Company
| Name | Category and Sector |
|---|---|
Bristol-Myers Squibb India Pvt Ltd.
 Bristol-Myers Squibb India Pvt Ltd. Discovers, develops and delivers medicines for immuno--oncology | |
Bristol-Myers Squibb India Pvt Ltd.
Bristol-Myers Squibb India Pvt Ltd. Discovers, develops and delivers medicines for immuno--oncology | |
Bristol-Myers Squibb Holdings Germany Verwaltungs GmbH | |
Bristol-Myers Squibb Holdings Germany Verwaltungs GmbH | |
Bristol-Myers Squibb SA (Switzerland) |
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.47% | -2.02% | +12.69% | -15.01% | 124B | |
| +0.17% | -1.72% | +23.18% | +210.44% | 929B | |
| -0.45% | +1.44% | +55.91% | +52.76% | 587B | |
| +1.76% | +3.61% | +20.03% | +53.25% | 409B | |
| +0.39% | +2.15% | +22.80% | +31.27% | 374B | |
| +0.28% | +9.16% | +29.42% | +33.43% | 320B | |
| +1.05% | +5.21% | +32.09% | +59.35% | 311B | |
| +1.82% | -0.43% | +46.26% | +12.75% | 301B | |
| -0.95% | -1.08% | -45.97% | -36.53% | 219B | |
| +0.82% | -3.94% | +26.80% | +53.79% | 199B | |
| Average | +0.49% | +1.46% | +22.32% | +45.55% | 377.24B | |
| Weighted average by Cap. | +0.36% | +1.25% | +26.83% | +77.87% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BMY Stock
- Company Bristol-Myers Squibb Company
Select your edition
All financial news and data tailored to specific country editions
